Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies

FDA approval of TREGZI marks the first and only precision-engineered allogeneic cell therapy for adults with hematological malignancies. The regulatory green light is a major positive catalyst for the program’s commercialization prospects and competitive positioning in transplant cell therapy.

Analysis

FDA approval of TREGZI marks the first and only precision-engineered allogeneic cell therapy for adults with hematological malignancies. The regulatory green light is a major positive catalyst for the program’s commercialization prospects and competitive positioning in transplant cell therapy.